LUPIN

July 9 (Reuters) - Lupin Ltd LUPN.NS:

• CO AND ZENTIVA SIGN AGREEMENT FOR CERTOLIZUMAB

• BOTH PARTIES WILL INVEST IN DEVELOPMENT OF NEW BIOSIMILAR

• TO RECEIVE INITIAL PAYMENT OF USD 10 MILLION, MILESTONE PAYMENTS UP TO USD 50 MILLION

Source text: ID:nNSE2vSMv7

Further company coverage: LUPN.NS

(([email protected];;))

July 1 (Reuters) - Indian drugmaker Lupin LUPN.NS said on Tuesday it will spin off its consumer healthcare business, LupinLife Consumer Healthcare into a separate unit, effective July 1.

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

June 30 (Reuters) - Lupin Ltd LUPN.NS:

• EXECUTED BUSINESS TRANSFER AGREEMENT FOR TRANSFER OF OTC BUSINESS TO LUPINLIFE CONSUMER

• TRANSFER OF OTC BUSINESS EFFECTIVE FROM JULY 01, 2025

Source text: [ID:]

Further company coverage: LUPN.NS

(([email protected];;))

Updates paragraph 1, adds details on Novo Nordisk and Eli Lilly

June 26 (Reuters) - India's drug regulator on Thursday approved the launch of pre-filled injector pens of Eli Lilly's LLY.N blockbuster weight-loss drug, Mounjaro, giving the company more options to compete with rival Novo Nordisk's NOVOb.CO recently launched Wegovy.

India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:

NOVO NORDISK

The Danish drugmaker launched its blockbuster weight-loss drug Wegovy in India on June 24, three months after Eli Lilly began marketing its rival product Mounjaro.

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.

Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply.

GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.

ELI LILLY

Lilly started selling Mounjaro in India in late March for diabetes and obesity, beating rival Novo to the market. The doses available were 2.5 mg and 5 mg vials.

On Thursday, Mounjaro KwikPen - for once-weekly use - was approved by the Central Drugs Standard Control Organization for six dose strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg.

SUN PHARMA

Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.

The drugmaker said earlier this month it expects to launch the drug in the next four to five years.

BIOCON

Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.

ZYDUS LIFESCIENCES

India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.

CIPLA

Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.

Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.

DR. REDDY'S

India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.

LUPIN

India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.

NATCO, MANKIND PHARMA, AUROBINDO PHARMA

Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.

Reuters was not able to independently verify the reports.

(Reporting by Mariam Sunny and Puyaan Singh in Bengaluru; Editing by Maju Samuel)

(([email protected];))

June 16 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - CO AND SINO UNIVERSAL PHARMACEUTICALS SIGN LICENSE AND SUPPLY AGREEMENT FOR TIOTROPIUM DPI IN CHINA

• LUPIN- LUPIN, SINO UNIVERSAL PHARMA SIGN LICENSE AND SUPPLY AGREEMENT FOR TIOTROPIUM DPI IN CHINA

• LUPIN- LUPIN WILL BE THE MARKETING AUTHORIZATION HOLDER AND RESPONSIBLE FOR MANUFACTURING

Further company coverage: LUPN.NS

(([email protected];))

May 20 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN AND HONEYWELL MOVE FORWARD JOINTLY WITH PLANS FOR HFO TECHNOLOGY IN INHALERS

Further company coverage: LUPN.NS

(([email protected];;))

May 8 (Reuters) - Lupin Ltd LUPN.NS:

• RECEIVES U.S. FDA APPROVAL FOR RALTEGRAVIR TABLETS USP, 600 MG

• ELIGIBLE FOR 180-DAY GENERIC EXCLUSIVITY FOR RALTEGRAVIR

Source text: ID:nBSE2fS4Wn

Further company coverage: LUPN.NS

(([email protected];;))

April 24 (Reuters) - Lupin Ltd LUPN.NS:

• RECEIVES APPROVAL FROM U.S. FDA FOR TOLVAPTAN TABLETS

  
  

Source text: [ID:]

Further company coverage: LUPN.NS

(([email protected];;))

April 17 (Reuters) - Lupin Ltd LUPN.NS:

• RECEIVES EIR FROM US FDA FOR NAGPUR FACILITY

• EIR ISSUED AFTER INSPECTION FROM JUNE 10 TO JUNE 13, 2024

Source text: ID:nBSE4mtxpR

Further company coverage: LUPN.NS

(([email protected];;))

** India's Zydus Lifesciences ZYDU.NS and Lupin LUPN.NS shed 6.6% and 3.8%, respectively

** Drugmakers lose patent litigation case in US for mirabegron, a generic version of Astellas Pharma's 4503.T bladder disorder drug Myrbetriq

** ZYDU and LUPN top losers on pharma index .NIPHARM which is down 0.2%

** It is a negative development for Zydus and Lupin as loss in litigation implies that they have to withdraw the drug from the market and could see some financial penalty, says Equirus

** Brokerage estimates $35 mln in quarterly sales from mirabegron for ZYDU and $25-30 mln for LUPN

** YTD, ZYDU drops ~15% while LUPN falls ~18%; pharma index down 11%

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Adds analyst comments in paragraphs 11-12, updates share moves throughout

By Manas Mishra and Ananta Agarwal

April 9 (Reuters) - Global drugmakers' stocks dropped across the board after U.S. President Donald Trump reiterated plans for a "major" tariff on pharmaceutical imports, threatening an interwoven global supply chain, and as his country-specific reciprocal tariffs took effect, leading to more pain in global markets.

Pharmaceutical imports were initially exempt from Trump's first set of reciprocal tariffs last week — but his administration has since indicated that levies on the sector, which in the past has been excluded from such actions, are coming.

The U.S. president has said the tariffs will incentivize drug companies to move operations to the United States. However, analysts and companies have raised concerns about the difficulty in setting up manufacturing in the country.

Shares of major U.S. drugmakers Amgen AMGN.O, AbbVie ABBV.N, Pfizer PFE.N, Merck MRK.N and Eli Lilly LLY.N fell between 3% and 6% in premarket trading.

In Europe, a basket of healthcare stocks .SXDP fell 5% to its lowest since October 2022, leading losses among sectoral indexes on the region-wide STOXX 600 .STOXX, which was down 3.3% at 1013 GMT. The index was heading for its biggest one-day drop since March 2020.

Trump had also threatened the duties on Friday after his first set of "reciprocal" tariffs exempted pharma products. Trump has not said when and by how much he plans to raise levies on pharma imports.

"While the details are scant, we are strongly opposed to tariffs on any pharmaceuticals — these will likely do little to shift manufacturing back to the U.S.," said BMO Capital Markets analyst Evan Seigerman.

"Given the complexity of the pharma supply chain, we do not expect the industry to make any major changes. These current tariffs are being pursued under emergency powers, which at worse will last until the end of the current administration and could end sooner with an act of Congress."

Seigerman also pointed to concerns over recent layoffs at the U.S. Food and Drug Administration, saying the worries were now compounded by the "real talk" of pharma tariffs.

ADDITIONAL COSTS, LONG WAIT FOR PRODUCTION

Europe and the U.S. have interconnected supply chains for medicines. The United States depends on medicines partly produced in Europe that bring in hundreds of billions of dollars in revenue.

Bernstein analyst Courtney Breen wrote in a note that her worst-case scenario assumes tariffs could be steep, leading to about $53 billion in additional costs paid for pharmaceutical imports.

If companies did choose to bring new manufacturing to the United States, Breen expects additional spend of $2 billion for each new "green field" site and a five-year runway to production.

EU medical and pharmaceutical product exports to the U.S. totaled about 90 billion euros ($97 billion) in 2023, according to latest Eurostat data.

Shares of AstraZeneca AZN.L, GSK GSK.L, Roche ROG.S, Sanofi SASY.PA and Novartis NOVN.S fell between 5% and 6.5% in Europe. Meanwhile, Indian pharmaceutical stocks .NIPHARM closed nearly 2% lower, dragging down the benchmark Nifty 50 .NSEI by 0.6%.

IPCA Laboratories IPCA.NS, Glenmark Pharma GLEN.NS and Biocon BION.NS were the top losers by percentage on the pharma index in Mumbai, ending the trading session between 4% and 5.5% lower.

India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. The United States accounts for a third of India's overall pharma exports.

(Reporting by Kashish Tandon, Ananta Agarwal and Manas Mishra in Bengaluru and Anna Pruchnicka in Gdansk; Editing by Savio D'Souza, Mrigank Dhaniwala and Shounak Dasgupta)

(([email protected]))

By Kashish Tandon

April 4 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 4.4% on Friday, wiping out gains from the previous session, after U.S. President Donald Trump threatened steep tariffs on the sector.

"Pharma (tariffs) is going to be starting to come in, I think, at a level that you haven't really seen before," Trump told reporters aboard Air Force One.

"That will be announced in the near future, and is under review right now," Trump said.

The index was among the top sectoral losers by percentage on the benchmark Nifty 50 .NSEI, which was down about 1.2% at 11:25 a.m. IST.

All 20 constituents of the pharma index were trading in the red, with Sun Pharma SUN.NS, Dr Reddy's REDY.NS and Cipla CIPL.NS being the biggest drags.

Lupin LUPN.NS, Aurobindo Pharma ARBN. and Ipca Laboratories IPCA.NS fell about 6.5% each, and were the top losers by percentage.

Trump imposed a 10% tariff on most U.S. imports earlier this week, as well as much higher levies on dozens of rivals and allies alike, but temporarily exempted some goods, including pharmaceuticals, benefiting major exporters including India, Japan and Ireland.

Pharma stocks were a rare bright spot on Thursday as global drugmakers gained on relief that their products remained temporarily shielded from the tariffs.

However, executives and analysts had warned it was premature to celebrate as levies were still likely to come.

"If these tariffs are introduced, the manufacturers will have no choice but to pass on the impact to consumers," said Vishal Manchanda, an analyst at Systematix Institutional Equities.

Indian drugmakers have been on a 'wait and watch' mode and also raised concerns on the difficulty in setting up manufacturing in the U.S., a move that would increase their costs.

Trump in his Wednesday address had predicted pharma companies would come "roaring back" to the U.S, and warned that "they got a big tax to pay" if they don't.

(Reporting by Kashish Tandon in Bengaluru; Editing by Varun H K)

(([email protected]; 8800437922;))

April 2 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN LTD - UNIT LUPIN HEALTHCARE UK ACQUIRES RENASCIENCE PHARMA

• LUPIN LTD - ACQUISITION COST GBP 12.3 MILLION

• LUPIN LTD - ACQUISITION TO EXTEND LUPIN'S SPECIALTY PHARMA PORTFOLIO IN UK

Source text: ID:nNSE13ZqF0

Further company coverage: LUPN.NS

(([email protected];))

Updates March 20 story with Novo Nordisk comment on Wegovy launch timing in paragraph 11

By Rishika Sadam

HYDERABAD, March 21 (Reuters) - Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.

U.S.-based Lilly LLY.N and Danish Novo Nordisk NOVOb.CO have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers' valuations.

Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.67) for a 5 mg vial and 3,500 rupees ($40.54) for a 2.5 mg vial, its lowest doses, the company told Reuters exclusively. Its highest dose is 15 mg.

A patient in India may have to spend about $200 a month when taking a weekly dose of 5 mg, subject to doctor's prescription.

Mounjaro carries a list price of $1,086.37 for each monthly fill in the U.S., but the amount patients pay largely depends on their insurance plan. Lilly also offers 5 mg, 7.5 mg and 10 mg vials of Zepbound, with prices around $499 for a month's supply if customers pay directly in cash without any third-party entities.

Chemically known as tirzepatide, Mounjaro is currently sold in the UK and Europe under the same brand name for both diabetes and weight loss. It is sold as Zepbound for obesity in the U.S.

Lilly, however, said that the pricing in different geographies cannot be compared given significant variation in healthcare systems, economies and reimbursement policies in each country.

"(Mounjaro) launch is ahead of Novo Nordisk and the first mover advantage should help ... but pricing seems high (for the Indian market). At the highest dose, a patient will have to spend close to 700,000 rupees (around $8,100) per annum," Vishal Manchanda, analyst at Systematix Institutional Equities said.

Novo's weight-loss drug, Wegovy, can cost non-insured U.S. patients more than $1,000 a month.

Novo's India team has been pushing the global leadership to launch Wegovy as early as 2025 in the country as opposed to the company's target of a 2026 launch.

The drugmaker told Reuters that Wegovy has already been approved in India, but said it did not have a confirmed date for the medicine's launch there.

The company's shares were down 0.6% at 1145 GMT, underperforming the broader European market .STOXX. Shares of U.S.-based Lilly rose as much as 2.07% to $854.39 on Thursday.

Novo's stock has fallen over 12% so far this year, while Lilly's has jumped 8%.

Novo is not the only competition Lilly will have to confront in India. Local drugmakers such as Sun Pharma SUN.NS, Cipla CIPL.NS, Dr. Reddy's REDY.NS and Lupin LUPN.NS have been racing to make generic versions of these drugs to grab a share of the global market estimated to be worth $150 billion in the next decade.

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.

"The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India," said President and General Manager Winselow Tucker at Lilly India.

Obesity and diabetes rates in India, a country of more than 1.4 billion people, have been steadily climbing. The number of adults with diabetes is set to increase to over 124 million by 2045 from 74.2 million in 2021, according to International Diabetes Federation.

Meanwhile, a government survey conducted between 2019 and 2021 showed that 24% of women and nearly 23% of men between the ages of 15 and 49 were either overweight or obese, up from 20.6% of women and 19% of men in 2015-2016.

Wegovy and Novo's diabetes drug, Ozempic — which has the same main ingredient — and Mounjaro, belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.

($1 = 86.3425 Indian rupees)

(Reporting by Rishika Sadam in Hyderabad, Maggie Fick in London and Bhanvi Satija in Bengaluru; Additional reporting by Manvi Pant in Bengaluru; Editing by Janane Venkatraman, Alan Barona and Tomasz Janowski)

(([email protected]; [email protected]))

March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.

India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:

NOVO NORDISK

The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.

Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.

SUN PHARMA

Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.

The drugmaker said earlier this month it expects to launch the drug in the next four to five years.

BIOCON

Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.

ZYDUS LIFESCIENCES

India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.

CIPLA

Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.

Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.

DR. REDDY'S

India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.

LUPIN

India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.

NATCO, MANKIND PHARMA, AUROBINDO PHARMA

Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.

Reuters was not able to independently verify the reports.

(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)

(([email protected];))

March 18 (Reuters) - Lupin Ltd LUPN.NS:

• SUBSIDIARY LUPINLIFE CONSUMER HEALTHCARE INCORPORATED

Source text: ID:nBSE1s9BDw

Further company coverage: LUPN.NS

(([email protected];;))

March 7 (Reuters) - Lupin Ltd LUPN.NS:

• LAUNCHES RIVAROXABAN TABLETS USP, 2.5MG IN UNITED STATES

Source text: ID:nBSE8cbHCM

Further company coverage: LUPN.NS

(([email protected];))

By Mike Scarcella

Feb 18 (Reuters) - Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who accused the company of conspiring with industry rivals to illegally fix prices.

Attorneys for the plaintiffs, including the City of Providence, Rhode Island and a New York City police employee benefits plan, asked U.S. District Judge Cynthia Rufe in Philadelphia on Friday to approve the settlement.

Sandoz denied any wrongdoing in agreeing to settle. The company said it will cooperate with the plaintiffs as they pursue claims against other drugmakers.

The antitrust case includes several drug makers that were not part of Friday's settlement, including Pfizer, Teva and Lupin. The companies did not immediately respond to requests for comment and have denied wrongdoing.

Sandoz and attorneys for the plaintiffs, "end-purchasers" including consumers who bought Sandoz drugs from pharmacies, did not immediately respond to requests for comment.

The settlement period covers some purchases between 2009 and 2019 for drugs, including the antidepressants amitriptyline and clomipramine, and for clobetasol, which is used to treat some skin conditions.

The settlement class likely includes millions of members with claims tied to Sandoz’s alleged price-fixing, the plaintiffs' lawyers told the court.

Their court filing said “continued litigation of the claims against Sandoz would be protracted and without guarantee of any recovery.”

The attorneys said they will seek up to $91.6 million in legal fees and $26 million in litigation expenses.

Sandoz last year agreed to pay $265 million to resolve related claims lodged in the litigation by a group of wholesale drug purchasers and others.

The case is In re Generic Pharmaceuticals Pricing Antitrust Litigation, U.S. District Court for the Eastern District of Pennsylvania, No. 2:16-MD-02724.

For end-payor class: Roberta Liebenberg and Jeffrey Istvan of Fine, Kaplan and Black

For Sandoz: Matthew Kent of Alston & Bird

Read more:

Drugmakers Apotex, Heritage to pay $49 mln to resolve states' price-fixing claims

Ex-Sandoz exec gets probation for price-fixing after cooperation deal

US drops price-fixing case against former Taro Pharmaceutical executive

** Drug manufacturer Lupin LUPN.NS up 3.79% to 2102 rupees

** Co's Q3 core profit margin expands 402 basis points y/y

** Analysts expect co to sustain high U.S. sales growth led by high value launches such as key diuretic Tolvaptan

** Co has 6-months exclusivity for Tolvaptan during which it aims to get 30-40% volume share

** "We see semaglutide (used for GLP-1 weight loss drug) as a key growth driver"- HSBC

** Nomura expects growth recovery in India due to Lupin's strong presence in chronic therapies

** Adds, "We expect Lupin to address GLP-1 opportunities in India and emerging markets from FY27"

** Including session's gains, LUPN up 30.4% in last 12 months

** LUPN rated 'hold' on avg by 32 analysts- LSEG compiled data

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

Feb 10 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN LTD - CO AND NATCO RECEIVE U.S. FDA APPROVAL FOR BOSENTAN TABLETS

Source text: ID:nBSEb28kSJ

Further company coverage: LUPN.NS

(([email protected];;))

Feb 3 (Reuters) - Lupin Ltd LUPN.NS:

• GETS TENTATIVE APPROVAL FROM U.S. FDA FOR DARUNAVIR, COBICISTAT TABLETS

• GETS TENTATIVE APPROVAL FROM U.S. FDA FOR EMTRICITABINE, TENOFOVIR ALAFENAMIDE TABLETS

Further company coverage: LUPN.NS

(([email protected];;))

Jan 9 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN - RECEIVES TENTATIVE APPROVAL FROM U.S. FDA FOR IVACAFTOR ORAL GRANULES

Source text: [ID:]

Further company coverage: LUPN.NS

(([email protected];;))

** Shares of India's Lupin LUPN.NS rise 2.6% to a record high of 2370.6 rupees, in an otherwise weak broader market

** LUPN among top pct gainers in the Nifty pharma index .NIPHARM, which is up 0.9%

** Drugmaker buys diabetes drug Huminsulin in India from Eli Lilly LLY.N; no financials disclosed

** Over 2 mln LUPN shares traded, over twice its 30-day avg

** Analysts' avg rating on stock is "hold," same as for Dr Reddy's REDY.NS and Cipla CIPL.NS - LSEG

** Their median PT on LUPN is 2259 rupees - LSEG

** YTD stock has jumped 78% vs 39% gain in Nifty pharma

(Reporting by Aleef Jahan in Bengaluru)

(([email protected];))

Dec 18 (Reuters) - Lupin Ltd LUPN.NS:

• GOT APPROVAL FROM U.S. FDA FOR ITS ANDA FOR EMTRICITABINE, TENOFOVIR ALAFENAMIDE TABLETS

Source text: ID:nBSE75XgNP

Further company coverage: LUPN.NS

(([email protected];))

Dec 13 (Reuters) - Lupin Ltd LUPN.NS:

• ACQUIRES ANTI-DIABETES TRADEMARKS FROM BOEHRINGER INGELHEIM

• TRADEMARK RIGHTS TO BE TRANSFERRED TO LUPIN BY MARCH

Source text: ID:nBSE9zxDqZ

Further company coverage: LUPN.NS

(([email protected];))

Dec 9 (Reuters) - Life Insurance Corporation of India LIFI.NS:

• LIFE INSURANCE CORP OF INDIA CUTS STAKE IN LUPIN BY 2.027% TO 2.542% - EXCHANGE FILING

Source text: ID:nBSE1Ftvv4

Further company coverage: LIFI.NS

(([email protected];))

Dec 2 (Reuters) - Lupin Ltd LUPN.NS:

• GOT TENTATIVE APPROVAL FROM U.S. FDA FOR SITAGLIPTIN AND METFORMIN HYDROCHLORIDE TABLETS

Source text: [ID:]

Further company coverage: LUPN.NS

(([email protected];;))

Nov 7 (Reuters) - Lupin Ltd LUPN.NS:

• Q2 CONSOL NET PAT 8.53 BILLION RUPEES; IBES PROFIT EST. 7.29 BILLION RUPEES

• Q2 CONSOL TOTAL REVENUE FROM OPERATIONS 56.73 BILLION RUPEES; IBES EST. 55.35 BILLION RUPEES

Source text: ID:nnAPN2DJ2DJ

Further company coverage: LUPN.NS

(([email protected];;))

Oct 15 (Reuters) - Lupin Ltd LUPN.NS:

• LAUNCHES FIRST GENERIC OF PRED FORTE® IN UNITED STATES

• LUPIN LAUNCHES FIRST GENERIC OF PRED FORTE IN UNITED STATES

Source text for Eikon: ID:nBSE3mg5BW

Further company coverage: LUPN.NS

(([email protected];;))

Sept 18 (Reuters) - Lupin Ltd LUPN.NS:

• ENTERED INTO NON-EXCLUSIVE PATENT LICENSE AGREEMENT WITH TAKEDA PHARMACEUTICAL

• AGREEMENT TO COMMERCIALIZE VONOPRAZAN TABLETS IN INDIAN MARKET

• TAKEDA HAS GRANTED CO NON-EXCLUSIVE PATENT RIGHTS TO COMMERCIALIZE VONOPRAZAN IN INDIA

Source text for Eikon: ID:nBSEcgd832

Further company coverage: LUPN.NS

(([email protected];))